Five-Year Cutoff on Tamoxifen Adjuvant Therapy Called Off Base Advice

[tousled1]

SAN ANTONIO, Dec. 16 -- The consensus that tamoxifen is limited to a five-year therapeutic lifetime against a recurrence of breast cancer is flawed, found a major international trial that suggests longer treatment is better

To read full article: http://www.medpagetoday.com/MeetingCoverage/SABCSMeeting/tb/7715